



cagrilintide dosage chart

Cagrilintide in trials is given as a once-weekly subcutaneous injection, with doses escalated over several weeks to reduce gastrointestinal side effects and reach a maintenance dose that may differ depending on whether it is used alone or combined with a GLP-1 agonist such as semaglutide. [\[1\]](#) [\[2\]](#)

Key points before the chart

- Cagrilintide is still an investigational (not yet approved) drug, and all dosing comes from clinical trials or research-oriented summaries, not from official prescribing information. [\[3\]](#) [\[4\]](#) [\[1\]](#)
- Any use outside a trial should only be under the direct supervision of a clinician experienced with obesity medications, since there is no standardized “clinical” dose chart yet. [\[5\]](#) [\[2\]](#)

Once-weekly dose-escalation (common research pattern)

The table below summarizes a commonly used once-weekly escalation schedule that appears in phase 2/3 obesity studies and in research-oriented dosage summaries, especially when cagrilintide is combined with semaglutide (“CagriSema”). [\[2\]](#) [\[6\]](#) [\[7\]](#)

Week range	Cagrilintide weekly dose	Typical context
1–4	0.25 mg once weekly	Starting dose to improve tolerability in CagriSema trials and research protocols. [2] [6] [7]
5–8	0.5 mg once weekly	First step up in 4-week increments. [2] [7]
9–12	1.0 mg once weekly	Intermediate dose during titration. [2] [7]
13–16	1.7 mg once weekly	Final titration step before full “maintenance” dose. [2] [6] [7]
≥17	2.4 mg once weekly	Common maintenance dose for cagrilintide alone or in fixed-dose combination with semaglutide in long-term obesity trials. [2] [6] [4]

Dose ranges in clinical studies

- Monotherapy trials have evaluated fixed once-weekly doses of 0.3, 0.6, 1.2, 2.4, and 4.5 mg, generally after a shorter dose-escalation period of up to about 6 weeks. [\[8\]](#) [\[1\]](#) [\[3\]](#)
- Combination studies with semaglutide typically target 2.4 mg of each drug once weekly after stepwise escalation; some research protocols explore cagrilintide up to 4.5 mg once

weekly when used alone. [6] [9] [2]

If you share what indication and co-medications (e.g., semaglutide, tirzepatide) you are thinking about, a more tailored, clinician-discussion-ready chart can be laid out.



1. <https://pubmed.ncbi.nlm.nih.gov/34798060/>
2. <https://www.peptides.org/cagrilintide-dosage/>
3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)01751-7/abstract](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01751-7/abstract)
4. <https://pubmed.ncbi.nlm.nih.gov/40544432/>
5. <https://swolverine.com/en-ca/blogs/blog/cagrilintide-benefits-dosage-and-weight-loss-potential-explained>
6. <https://mediacenteratypen.nejmgroup-production.org/NEJMoa2502081.pdf>
7. <https://www.medscape.com/viewarticle/993665>
8. <https://pace-cme.org/news/amylin-analogue-reduces-body-weight-in-individuals-with-overweight-and-obesity/2456114/>
9. <https://www.sciencedirect.com/science/article/abs/pii/S0140673623011637>
10. <https://www.peptides.org/dosage-guideline/>
11. <https://www.doctronic.ai/blog/cagrilintide-dosage-with-tirzepatide/>
12. <https://www.news-medical.net/news/20250623/Cagrilintide-and-semaglutide-together-drive-record-weight-loss-in-global-trial.aspx>
13. <https://www.semanticscholar.org/paper/Once-weekly-cagrilintide-for-weight-management-in-a-Lau-Erichsen/7eec2610e06b95d47695205d4eaa741f4502a65b>
14. <https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565>
15. <https://trial.medpath.com/clinical-trial/511825387e45ef6a/nct06388187-efficacy-safety-cagrilintide-semaglutide>
16. <https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15951>
17. <https://clinicaltrials.gov/study/NCT07010432>
18. <https://ctv.veeva.com/study/a-research-study-to-compare-blood-levels-of-cagrilintide-and-semaglutide-after-single-doses-of-diffe>
19. <https://sciencehub.novonordisk.com/search.molecules.cagrilintide.html>
20. <https://www.bioworld.com/articles/683834-phase-ib-data-for-cagrilintide-plus-semaglutide-in-overweight-or-obese-subjects>